Study Title
A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC)
Protocol ID
ARAR2221
Condition/s
Stage II-IV Nasopharyngeal Carcinoma AJCC v8
Diagnosis Stage
Newly diagnosed
Location
NSW, VIC, WA, NZ
Sponsor
Children's Oncology Group
Collaborators
Children's Oncology Group
Links
Trial Status
Preparing to Open
Sites
Perth Children's Hospital
Starship Children's Hospital
John Hunter Children's Hospital
The Royal Children's Hospital
Starship Children's Hospital
John Hunter Children's Hospital
The Royal Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
Up to 21 Years
International registry ID's
NCT06064097
| Study Title | A Phase 2 Study Using Chemoimmunotherapy with Gemcitabine Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC) |
|---|---|
| Protocol ID | ARAR2221 |
| Disease (Sub Disease) | Stage II-IV Nasopharyngeal Carcinoma AJCC v8 |
| Diagnosis Stage | Newly diagnosed |
| Location | NSW / VIC / WA / NZ |
| Sponsor | Children's Oncology Group/ |
| Collaborators | Children's Oncology Group/ |
| Links | https://clinicaltrials.gov/study/NCT06064097 |
| Trial Status | Preparing to Open |
| Sites | Perth Children's Hospital / Starship Children's Hospital/ John Hunter Children's Hospital/ The Royal Children's Hospital/ |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | Up to 21 Years |
| International registry ID's | NCT06064097 |